Healthcare Services

Glomerulonephritis Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Glomerulonephritis Market Between 2026 And 2030?

The glomerulonephritis market size has shown consistent expansion in recent years. It is projected to increase from $11.61 billion in 2025 to $12.18 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.0%. The growth observed in the historical period is attributable to the prevalence of autoimmune disorders, the adoption of kidney biopsies, the expansion of nephrology clinics, the availability of immunosuppressive drugs, and the enlargement of diagnostic laboratories.

The glomerulonephritis market is anticipated to show consistent expansion over the upcoming years. It is projected to achieve a value of $14.66 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.7%. This expected growth within the forecast period stems from progress in renal diagnostics, the evolution of precision nephrology, a rise in the incidence of chronic kidney disease, the broadening of specialized nephrology services, and better adherence to treatment regimens. Significant developments foreseen in this period involve a heightened focus on the early detection of kidney disease, an increasing application of immunosuppressive treatments, the wider adoption of biomarker-based testing, an expansion of services supporting dialysis, and enhanced management of chronic conditions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Glomerulonephritis Market?

An increasing incidence of kidney disorders is anticipated to fuel the expansion of the glomerulonephritis market moving forward. Kidney disorders refer to a diverse set of conditions that impair the structure or function of the kidneys, leading to compromised filtration, waste removal, and fluid balance. The rising occurrence of these disorders stems from factors such as aging populations, escalating rates of chronic diseases like diabetes and hypertension, and lifestyle choices. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, which in turn leads to impaired kidney filtration and function. For instance, in June 2023, Kidney Research UK reported that an estimated 7.19 million people in the UK were affected by chronic kidney disease in 2023, representing more than 10% of the UK population, with projections indicating an increase to 7.61 million people by 2033. Therefore, the growing prevalence of kidney disorders will be a significant driver for the glomerulonephritis market.

Which Market Segments Are Examined In The Glomerulonephritis Market Study?

The glomerulonephritis market covered in this report is segmented –

1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis

2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis

3) By Treatment: Medication, Surgery, Dialysis, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome

2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis

What Key Trends Are Influencing The Development Of The Glomerulonephritis Market?

Leading companies in the glomerulonephritis market are concentrating on developing advanced non-immunosuppressive treatments to address unmet medical needs and improve patient outcomes. Non-immunosuppressive treatments are therapies designed not to weaken or suppress the immune system, aiming to treat conditions without compromising immune function. For instance, in September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, launched FILSPARI (sparsentan), which received approval from the Food and Drug Administration (FDA) for the treatment of IgA nephropathy, a kidney disease. This drug is the only non-immunosuppressive treatment demonstrated to significantly slow the decline of kidney function in these patients. FILSPARI’s approval represents a major breakthrough in the therapy for IgA nephropathy, which is the most common type of primary glomerulonephritis. This therapy provides a new option for patients who previously had limited choices. This approval highlights Travere’s commitment to enhancing patient outcomes in kidney disease.

Who Are The Primary Competitors In The Glomerulonephritis Market?

Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., Chinook Therapeutics, Purespring Therapeutics, Walden Biosciences, Visterra Inc.

Read the full glomerulonephritis market report here:

https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report

What Are The Leading Geographic Regions In The Glomerulonephritis Market?

North America was the largest region in the glomerulonephritis market in 2025. The regions covered in the glomerulonephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Glomerulonephritis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp

Browse Through More Reports Similar to the Global Glomerulonephritis Market 2026, By The Business Research Company

Glioma Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Sarcoma Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Adult Malignant Glioma Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795